Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib

X
Trial Profile

CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rucaparib (Primary)
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; Registrational
  • Acronyms CATCH-R
  • Sponsors Clovis Oncology [CEASED]; zr pharma
  • Most Recent Events

    • 28 Mar 2024 This trial has been discontinued in Czechia, according to European Clinical Trials Database record.
    • 12 Mar 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
    • 11 Aug 2023 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top